- Home
- MVO vs LGVN Comparison
MVO vs LGVN Comparison
Compare MVO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | LGVN |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 25.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVO | LGVN |
|---|---|---|
| Price | $1.50 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 130.1K | ★ 208.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | $0.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.97 | $0.48 |
| 52 Week High | $6.19 | $1.80 |
Technical Indicators
Market Signals| Indicator | MVO | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 52.50 |
| Support Level | $1.33 | $0.73 |
| Resistance Level | $1.57 | $0.84 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 21.94 | 65.72 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.